A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.

被引：0
|
作者：
Sato, Yasushi
Sagawa, Tamotsu
Takahashi, Yasuo
Ohnuma, Hiroyuki
Hamaguchi, Kyoko
Hirakawa, Masahiro
Fujikawa, Koshi
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Takayama, Tetsuji
机构：
[1] Tokushima Univ, Grad Sch Biomed Sci, Tokushima, Japan
[2] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[3] Sapporo Med Univ, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
    Yasushi Sato
    Tamotsu Sagawa
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Yasuo Takahashi
    Kyoko Hamaguchi
    Koshi Fujikawa
    Takayuki Nobuoka
    Koichi Okamoto
    Hiroshi Miyamoto
    Naoki Muguruma
    Ichiro Takemasa
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 161 - 167
  • [2] A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
    Sato, Yasushi
    Sagawa, Tamotsu
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Yasuo
    Hamaguchi, Kyoko
    Fujikawa, Koshi
    Nobuoka, Takayuki
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takemasa, Ichiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 161 - 167
  • [3] Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer.
    Vestermark, Lene Weber
    Jensen, Helle Anita
    Schoennemann, Katrine Rahbek
    Krogh, Merete
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A PHASE II STUDY OF S-1 AND OXALIPLATIN AS FIRST-LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER
    Kim, H. G.
    Kang, M.
    Kim, S.
    Lee, S. I.
    Lee, G.
    Kang, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 182 - 182
  • [5] A phase II study of S-1 and oxaliplatin as first-line therapy for patients with recurrent or metastatic gastric cancer
    Kim, H.
    Lee, G.
    Kim, H.
    Lee, O.
    Hwang, I.
    Kang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [7] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [8] Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
    Kouroussis, C
    Androulakis, N
    Kakolyris, S
    Souglakos, J
    Kotsakis, T
    Mavroudis, D
    Katsogridakis, K
    Vardakis, N
    Hatzidaki, D
    Samonis, G
    Vlachonikolis, J
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 862 - 869
  • [9] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [10] Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer
    Hyeong Su Kim
    Min-Hee Ryu
    Dae Young Zang
    Baek-Yeol Ryoo
    Dae Hyun Yang
    Ji Woong Cho
    Man Sup Lim
    Min-Jeong Kim
    Boram Han
    Dae Ro Choi
    Jung Han Kim
    Joo Young Jung
    Hunho Song
    Choong Kee Park
    Yoon-Koo Kang
    Gastric Cancer, 2016, 19 : 579 - 585
12345